211 related articles for article (PubMed ID: 8841151)
1. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
2. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study.
Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC
Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816
[TBL] [Abstract][Full Text] [Related]
3. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.
Wermeling DP; Miller JL; Archer SM; Rayens MK; Rudy AC
J Clin Pharmacol; 2005 Aug; 45(8):969-73. PubMed ID: 16027409
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).
Riggs SM; Hawkins MG; Craigmill AL; Kass PH; Stanley SD; Taylor IT
Am J Vet Res; 2008 May; 69(5):596-603. PubMed ID: 18447789
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
Shyu WC; Morgenthien EA; Barbhaiya RH
Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of butorphanol in horses after intramuscular injection.
Sellon DC; Papich MG; Palmer L; Remund B
J Vet Pharmacol Ther; 2009 Feb; 32(1):62-5. PubMed ID: 19161457
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.
Vachharajani NN; Shyu WC; Greene DS; Barbhaiya RH
Biopharm Drug Dispos; 1997 Apr; 18(3):191-202. PubMed ID: 9113342
[TBL] [Abstract][Full Text] [Related]
10. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
11. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
12. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
[TBL] [Abstract][Full Text] [Related]
13. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.
Shyu WC; Pittman KA; Robinson DS; Barbhaiya RH
Eur J Clin Pharmacol; 1993; 45(6):559-62. PubMed ID: 8157043
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration.
Zhao Y; Tao T; Wu J; Pi J; He N; Chai X; Chen Q
J Pharm Pharmacol; 2008 Sep; 60(9):1149-54. PubMed ID: 18718117
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of butorphanol in broiler chickens.
Singh PM; Johnson C; Gartrell B; Mitchinson S; Chambers P
Vet Rec; 2011 Jun; 168(22):588. PubMed ID: 21628341
[TBL] [Abstract][Full Text] [Related]
18. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls.
Deroubaix X; Lins RL; Lens S; Allemon A; Jeanbaptiste B; Poli G; Acerbi D; Stockis A; Ventura P
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):386-91. PubMed ID: 9707354
[TBL] [Abstract][Full Text] [Related]
19. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.
Shyu WC; Morgenthien EA; Pittman KA; Barbhaiya RH
Eur J Clin Pharmacol; 1994; 47(1):57-60. PubMed ID: 7988625
[TBL] [Abstract][Full Text] [Related]
20. Influence of age on the pharmacokinetics of butorphanol.
Ramsey R; Higbee M; Maesner J; Wood J
Acute Care; 1988; 12 Suppl 1():8-16. PubMed ID: 3344601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
